Table 5.

Adjusted Cox Proportional Hazard model for KS, systemic NHL, and CNS NHL survival time, stratified by cancer treatment.

	Adjusted RH (95% CI)	P-value	Adjusted RH (95% CI)	P-value
Kaposi’s sarcoma	No cancer treatment* N=894; 770 deaths		Received cancer treatment* N=1,416; 1230 deaths
HAART
No use	1.00 (reference)	-	1.00 (reference)	-
< 6 months use	1.01 (0.66–1.55)	0.97	0.86 (0.61–1.21)	0.38
≥6 months use	0.54 (0.38–0.76)	0.0004	0.37 (0.29–0.48)	<0.0001
Calendar Time
1990–1995	1.00 (reference)	-	1.00 (reference)	-
1996–1998	0.55 (0.44–0.76)	<0.0001	0.66 (0.54–0.81)	<0.0001
1999–2000	0.38 (0.24–0.61)	<0.0001	0.56 (0.38–0.81)	0.002
2001–2007	0.22 (0.12–0.39)	<0.0001	0.34 (0.21–0.56)	<0.0001
Systemic NHL	No cancer treatment** N=140; 128 deaths		Cancer treatment** N=563; 484 deaths
HAART
No use	1.00 (reference)	-	1.00 (reference)	-
< 6 months use	1.28 (0.42–3.86)	0.67	0.83 (0.49–1.39)	0.47
≥6 months use	0.58 (0.27–1.25)	0.16	0.79 (0.54–1.16)	0.25
Calendar Time
1990–1995	1.00 (reference)	-	1.00 (reference)	-
1996–1998	1.15 (0.69–1.91)	0.60	0.53 (0.39–0.72)	<0.0001
1999–2000	1.42 (0.58–3.47)	0.44	0.44 (0.27–0.71)	0.0008
2001–2007	0.34 (0.04–3.03)	0.34	0.41 (0.24–0.68)	0.0006
CNS NHL	No cancer treatment N=58; 56 deaths		Cancer treatment N=163; 158 deaths
HAART
No use	1.00 (reference)	-	1.00 (reference)	-
< 6 months use	0.50 (0.10–2.48)	0.40	0.90 (0.45–1.80)	0.77
≥6 months use	0.56 (0.12–2.53)	0.45	0.47 (0.22–1.05)	0.06
Calendar Time
1990–1995	1.00 (reference)	-	1.00 (reference)	-
1996–1998	2.04 (0.90–4.63)	0.09	1.06 (0.72–1.58)	0.76
1999–2007	0.67 (0.15–3.06)	0.60	0.90 (0.40–1.99)	0.79

CI=Confidence Interval; CNS=central nervous system; HAART=highly active antiretroviral therapy; NHL=non-Hodgkin lymphoma; RH = Relative Hazard.

^*Adjusted for cancer stage, CD4+ cell count at KS diagnosis, initial AIDS diagnosis, and age.

^**Adjusted for cancer stage, initial AIDS diagnosis, age, and sex.